Multiple Myeloma: « 20 » and « 100 » Ratios Cut-off applicable to Sebia FLC assays

Pubblicazione
Oct. 14, 2022

The « 20 » and « 100 » Ratios Cut-off can be used in routine with Sebia FLC assays for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis.

Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies – MDPI – 2019

Pubblicazione
Jan. 12, 2022

This special Issue related to newborn screening for Sickle Cell disease and other hemoglobinopathies tried to cover the most widely faced challenges in the field of newborn screening for SCD.

Experience and recommendations of a Major Cancer Center to use HYDRASHIFT daratumumab

Pubblicazione
Aug. 09, 2021

Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.

von Willebrand Factor and COVID-19

Pubblicazione
Jun. 17, 2021

Correlation of von Willebrand factor with the severity of COVID-9 progression.

HYDRASHIFT avoids monoclonal antibody interference on IMMUNOFIXATION

Pubblicazione
Jun. 14, 2021

The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with isatuximab or daratumumab.

Pitfalls and ceveats of A1AT diagnosis

Pubblicazione
Jun. 14, 2021

Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians.

Evaluation of Sebia’s isoelectrofocusing kit for A1AT

Pubblicazione
Jun. 14, 2021

Evaluation of Sebia’s isoelectrofocusing kit for A1AT with HYDRASYS.

International standardization of CDT measurement

Pubblicazione
Jun. 14, 2021

IFCC CDT-Working Group standardized the CDT measurement.